NEW YORK (360Dx) – Cytek Biosciences said today that the Chinese National Medical Products Administration has cleared the company's DxP Athena 13-color flow cytometer for use in that country.
The regulatory clearance means the instrument can be used as a clinical diagnostic tool in hospitals, laboratories, and clinics in China.
The DxP Athena leverages Cytek's DxP technology, which enables scientists to resolve dim populations in a multicolor format. Fremont, California-based Cytek said that the instrument is compact, hands-on, affordable, and easy to use, and assays need only microvolumes of cells and reagents. The amount of waste generation is minimal, and the company added that its QbSure QC product has also been approved by NMPA for use with the DxP Athena, which includes Cytek's validation beads and QbSure QC software.
Cytek CEO Wenbin Jiang said in a statement that NMPA clearance "opens the door for our entire range of flow cytometry solutions to be approved for clinical use in countries worldwide."